HLA-restricted, peptide-specific antigen binding proteins
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong Cheung, Dimiter Tassev, Jian Hu
Life of this patent
Estimating the term…
Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong Cheung, Dimiter Tassev, Jian Hu
Estimating the term…
Antigen binding proteins with T cell receptor-like paratopes, that is, with an antigen binding region specific for an human leukocyte antigen-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
An isolated antigen-binding protein comprising one of:
An isolated single-chain variable fragment (scFv) comprising the amino acid sequence set forth in SEQ ID NO:
An isolated scFv comprising a VH and a VL linked by an amino acid spacer, wherein the VH and VL respectively comprise the amino acid sequences set forth in SEQ ID NO:
Dependencies are inferred from the claim text.